QuidelOrtho sees FY25 Labs business growth in mid-single digits

Sees: Transfusion Medicine business growth, excluding Donor Screening, expected in the low single digits; Donor Screening revenue expected to be $40M-$50M for full-year 2025; Point of Care business growth, excluding excluding COVID-19, expected in the mid-single digits; China growth expected in the mid- to high-single digits. In Respiratory: Overall market size of 50-55M tests with greater than 50% of flu revenue coming from flu/COVID-19 combo test; Full-year 2025 COVID-19 revenue of $110-$140M; assumes no government contract revenue; No contribution from U.S. Savanna respiratory products in 2025. Comments taken from investor presentation slides.